FILTERED RESULTS
FILTERS
Ads Top
DARK MODE
CHART
    Filters
      Symbols
      Sentiment
      Impact
      Search
      FILTERED RESULTS

        

      Upgrade your plan
      Dashboard

      Roche Reports Positive Phase III Results for Sefaxersen in IgA Nephropathy Treatment

      Roche Holding AG, a Swiss multinational healthcare company, announced significant findings from its Phase III clinical trial of sefaxersen, a treatment aimed at reducing proteinuria in patients with IgA nephropathy. The study demonstrated that sefaxersen effectively lowered protein levels in urine, a key indicator of kidney function, which is crucial for managing this chronic kidney disease.

      IgA nephropathy, also known as Berger's disease, is characterized by the deposition of immunoglobulin A in the kidneys, leading to inflammation and potential kidney damage. The results from this trial are expected to provide a new therapeutic option for patients suffering from this condition, which currently has limited treatment alternatives.

      Roche's commitment to advancing treatments for kidney diseases is underscored by these promising results, which may pave the way for regulatory submissions and potential market approval in the near future. The company aims to address the unmet medical needs of patients with IgA nephropathy through innovative therapies.

      © 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

      Source: KLEA News

      .

      Terra Founder Do Kwon Sentenced to 15 Years in Prison for Fraud